Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	19.72	18.82	12.88	7.28	1.35	0.93
Research & Development	46.05	42.32	32.36	12.31	8	8.58
Operating Expenses	65.78	61.14	45.24	19.58	9.35	9.5
Operating Income	-65.78	-61.14	-45.24	-19.58	-9.35	-9.5
Interest Expense / Income	1.58	0.58	0	0	0	0
Other Expense / Income	-11.42	-9.35	-2.38	81.02	-2.02	-1.6
Pretax Income	-55.94	-52.37	-42.86	-100.61	-7.33	-7.91
Net Income	-55.94	-52.37	-42.86	-100.61	-7.33	-7.91
Preferred Dividends	0	0	0	0	0	-0.22
Net Income Common	-55.94	-52.37	-42.86	-100.61	-7.33	-7.69
Shares Outstanding (Basic)	60	49	41	20	0	0
Shares Outstanding (Diluted)	60	49	41	20	0	0
Shares Change	45.79%	19.72%	102.43%	4685.58%	-2.71%	-
EPS (Basic)	-1.06	-1.08	-1.06	-5.02	-17.48	-17.84
EPS (Diluted)	-1.06	-1.08	-1.06	-5.02	-17.48	-17.84
Free Cash Flow	-50.78	-43.08	-35.31	-18	-7.45	-6.82
Free Cash Flow Per Share	-0.85	-0.89	-0.87	-0.90	-17.77	-15.83
EBITDA	-54.18	-51.61	-42.69	-100.6	-7.33	-7.91
Depreciation & Amortization	0.18	0.18	0.17	0	0	0
EBIT	-54.36	-51.79	-42.86	-100.61	-7.33	-7.91

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).